TYRA
Tyra Biosciences, Inc.
NASDAQ · Healthcare · Biotechnology · US
$28.65
+15.25%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | — | — | — | — | — |
| Cost of Revenue | 138.0K | — | — | — | — |
| Gross Profit | (138.0K) | — | — | — | — |
| Operating Expenses | |||||
| R&D Expense | 126.2M | 102.9M | 80.1M | 62.5M | 43.0M |
| SG&A Expense | 34.1M | 29.8M | 24.1M | 17.4M | 15.9M |
| General & Admin Expense | 34.1M | 29.8M | 24.1M | 17.4M | 15.9M |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | — | — | — | — | — |
| Total Operating Expenses | 160.3M | 132.8M | 104.2M | 79.9M | 58.9M |
| Cost and Expenses | 160.5M | 132.8M | 104.2M | 79.9M | 58.9M |
| Operating Income (EBIT) | (160.5M) | (132.8M) | (104.2M) | (79.9M) | (58.9M) |
| Non-Operating | |||||
| Interest Income | 11.9M | 12.8M | 17.7M | 10.8M | 3.7M |
| Interest Expense | — | — | — | — | — |
| Net Interest Income | 11.9M | 12.8M | 17.7M | 10.8M | 3.7M |
| Other Non-Op Income/Expense | 11.9M | 12.8M | 17.7M | 10.8M | 3.6M |
| Non-Operating Income (excl Interest) | (11.9M) | (12.8M) | (17.7M) | (10.8M) | (3.6M) |
| EBT (Pre-Tax Income) | (148.6M) | (119.9M) | (86.5M) | (69.1M) | (55.3M) |
| Income Tax Expense | — | — | — | — | — |
| Bottom Line | |||||
| Net Income | (148.6M) | (119.9M) | (86.5M) | (69.1M) | (55.3M) |
| Earnings from Cont. Ops | (148.6M) | (119.9M) | (86.5M) | (69.1M) | (55.3M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (148.6M) | (119.9M) | (86.5M) | (69.1M) | (55.3M) |
| Per Share | |||||
| Basic EPS | ($2.40) | ($2.01) | ($1.51) | ($1.62) | ($1.23) |
| Diluted EPS | ($2.40) | ($2.01) | ($1.51) | ($1.62) | ($1.23) |
| Revenue Per Share | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Shares | |||||
| Basic Shares Outstanding | 66.0M | 59.6M | 57.2M | 42.7M | 41.9M |
| Diluted Shares Outstanding | 66.0M | 59.6M | 57.2M | 42.7M | 41.9M |
| Profitability Metrics | |||||
| EBITDA | (148.0M) | (119.4M) | (86.0M) | (68.8M) | (55.0M) |
| D&A | 539.0K | 546.0K | 519.0K | 357.0K | 296.0K |
| EBIT | (148.6M) | (119.9M) | (86.5M) | (69.1M) | (55.3M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026